NAYA Therapeutics Revenue

Biotechnology Research • Aventura, Florida, United States • 1-10 Employees

NAYA Therapeutics revenue & valuation

Annual revenue	$6,619,956
Revenue per employee	$736,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$21,200,000
Total funding	$9,500,000

Key Contacts at NAYA Therapeutics

Subhashis Sarkar

Director Of R&D

Armin Rath

Svp Head Of Product Development

Company overview

Headquarters	19505 Biscayne Blvd, Suite 2350, 3rd floor, Aventura, Florida 33180, US
Phone number	+19788789505
Website	nayatx.com
NAICS	541714
Employees	1-10
Socials

NAYA Therapeutics Email Formats

NAYA Therapeutics uses 1 email format. The most common is {first initial} (e.g., j@nayatx.com), used 100% of the time.

Format	Example	Percentage
{first initial}	j@nayatx.com	100%

About NAYA Therapeutics

NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing oncology outcomes through the development of next-generation bifunctional antibodies. NAYA has developed a versatile plug and play bifunctional antibody construct that promotes avidity and a synapse effect, enhancing precision tumor killing. The company has two priority development franchises, Hepatocellular Carcinoma (HCC) and Multiple Myeloma, with an expanding portfolio of highly-differentiated assets that currently includes: NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of HCC with a unique mechanism of action targeting non-responders to the current immunotherapy standard of care (70-85% of the current treatable market), cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025. NY-500, an AI-optimized PD-1 x VEGF bifunctional antibody aiming to be the first PD-1 x VEGF to market in HCC, with translational clinical and preclinical data in 2025 and Phase I/II in HCC to be initiated in early 2026. NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma with a unique mechanism of action enhancing safety & efficacy and a differentiated profile to daratumumab and T-Cell engagers, aiming to enroll patients in its Phase I/II clinical trials in early 2026. NAYA’s data has been presented at major oncology meetings including the American Society of Hematology (ASH), The American Association of Cancer Research (AACR), The Society for Immunotherapy of Cancer (SITC), and the European Society for Medical Oncology (ESMO). NAYA’s clinical development has been designed by its scientific advisory board of leading liver cancer and multiple myeloma experts to allow for early inflection points and accelerated development based on early data.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Entry

Vice President

C-Suite

Employees by Department

NAYA Therapeutics has 4 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore NAYA Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2025-02-13	14	$9,500,000

Funding Insights

$9,500,000

Total funding amount

$9,500,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

NAYA Therapeutics is located in Aventura, Florida, US.

You can reach NAYA Therapeutics at +19788789505.

NAYA Therapeutics generates an estimated annual revenue of $6,619,956. This revenue figure reflects the company's market position and business performance in its industry.

NAYA Therapeutics has an estimated valuation of $21,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

NAYA Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

NAYA Therapeutics has raised a total of $9,500,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at NAYA Therapeutics

Subhashis Sarkar

Director Of R&D

Armin Rath

Svp Head Of Product Development

4.8

40,000 users